| Role |
Name |
Disclosure |
Details |
| Author | Jonathan Rubenstein, MD, Staff Physician, Department of Urology, University of California, San Francisco | Nothing to disclose | Details | | Coauthor | Robert E Brannigan, MD, Associate Professor, Department of Urology, Northwestern Memorial Hospital | Nothing to disclose | Details | | Medical Editor | Daniel B Rukstalis, MD, Director of Urological Services, Geisinger Medical Center, Geisinger Medical Group | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Mark Jeffrey Noble, MD, Consulting Staff, Urologic Institute, Cleveland Clinic Foundation | Nothing to disclose | Details | | CME Editor | J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Director, Division of Minimally Invasive Urology, Department of Urology, University of Michigan Medical Center | Terumo Corporation Omeros Corporation | Details | | Chief Editor | Stephen W Leslie, MD, FACS, Founder and Medical Director of the Lorain Kidney Stone Research Center, Clinical Assistant Professor, Department of Urology, Medical College of Ohio | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Robert E Brannigan, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Daniel B Rukstalis, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Mark Jeffrey Noble, Managing Editor |
The contributor discloses no conflict of interest. |
|